Drug Trial Radar · NCT07629726
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Apr 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.
Conditions
- Hematologic Neoplasms
Interventions
KK2430Drug
KK2430 administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Level Toxicity (DLT)Time frame: Endpoint 28 days after first dose
- Adverse Events (AEs)Time frame: Signing of ICF through study completion for an average of 1.5 years
- Pregnancy TestTime frame: Screening through study completion, an average of 1.5 years
- ECG QT IntervalTime frame: Treatment period, an average of 3months
- ECG QRS IntervalTime frame: Treatment period, an average of 3months
- Vital Sign MeasurementsTime frame: Treatment period, an average of 3 months
- Vital Sign MeasurementsTime frame: Treatment period, an average of 3 months
- Vital Sign MeasurementsTime frame: Treatment period, an average of 3 months
- Vital Sign MeasurementsTime frame: Treatment period, an average of 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prisma Health
Greenville, South Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.